

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace prior versions and listings of claims in the application:

Claims 1-39 have been amended as follows: Underlines indicate insertions and ~~strikeouts~~ indicate deletions. Claims 2 and 40-41 were cancelled.

**Listing of claims:**

1. (Currently amended) A method of screening for a compound useful in the treatment of a disease or condition characterized by an immune cells disorder, wherein said cell expresses ecto-nucleoside triphosphate diphosphohydrolase (NTPDases), said method comprising the steps of contacting a candidate compound with a ecto-nucleoside triphosphate diphosphohydrolase (NTPDase), wherein said contacting is performed in an immune cell selected from the group consisting in normal T lymphocyte, normal B lymphocyte, normal NK cell, normal macrophage, normal monocyte, Jurkat cell, Raji cell, Ramos cell, MonoMac™ cell, K562 cell and U937 cell,

wherein the candidate compound is selected if the activity of said NTPDase is reduced in the presence of the candidate compound as compared to that in the absence thereof.

2. (Cancelled)

3. (Currently amended) A The method ~~as defined in~~ claim 21, wherein said immune cell is a T lymphocyte.

4. (Currently amended) A The method ~~as defined in~~ claim 21, wherein said immune cell is a B lymphocyte.

5. (Currently amended) A The method ~~as defined in~~ claim 21, wherein said immune cell is a Jurkat cell.

6. (Currently amended) A The method ~~as defined in~~ claim 21, wherein said immune cell is a Raji Cell.

7. (Currently amended) A The method ~~as defined in~~ claim 21, wherein said immune cell is a Ramos cell.

Application No. 11/511,133 – Amendment filed June 11, 2007 in response to Office Action dated January 16, 2007

8. (Currently amended) A ~~The~~ method as ~~defined in~~ claim 21, wherein said immune cell is a MonoMac™ cell.

9. (Currently amended) A ~~The~~ method as ~~defined in~~ claim 21, wherein said immune cell is a K562 cell.

10. (Currently amended) A ~~The~~ method as ~~defined in~~ claim 21, wherein said immune cell is a U937 cell.

11. (Currently amended) A ~~The~~ method as ~~defined in~~ claim 21, wherein said immune cell is a NK cell.

12. (Currently amended) A method for inhibiting an immune cell activity in a mammal, comprising targeting immune cells in the mammal with an effective amount of a NTPDase inhibitor, whereby said targeting inhibits the immune cell activity in the mammal.

13. (Currently amended) A ~~The~~ method as ~~recited in~~ claim 12, wherein said cells are normal lymphocytes.

14. (Currently amended) The method as ~~recited in~~ claim 13, wherein said normal cells are normal T lymphocytes.

15. (Currently amended) The method as ~~recited in~~ claim 14, wherein said activity is the T lymphocyte proliferation.

16. (Currently amended) The method as ~~recited in~~ claim 13, wherein said normal lymphocytes are normal B lymphocyte.

17. (Currently amended) The method as ~~recited in~~ claim 12, wherein said activity is the production of antibodies.

18. (Currently amended) A ~~The~~ method as ~~recited in~~ claim 12, wherein said cells are neoplastic lymphocytes.

19. (Currently amended) The method as ~~recited in~~ claim 18, wherein said neoplastic lymphocytes are neoplastic T lymphocytes.

Application No. 11/511,133 – Amendment filed June 11, 2007 in response to Office Action dated January 16, 2007

20. (Currently amended) The method ~~as recited in~~of claim 19, wherein said neoplastic T lymphocytes are Jurkat cells.

21. (Currently amended) The method ~~as recited in~~of claim 12, wherein said activity is induced by organ or tissue transplant.

22. (Currently amended) The method ~~as recited in~~of claim 12, wherein said activity is induced by an allergen.

23. (Currently amended) The method ~~as recited in~~of claim 12, wherein said activity is induced in autoimmune diseases.

24. (Currently amended) ~~A~~The method ~~as recited in~~of claim 12, wherein said NTPDase inhibitor is selected from the group consisting of BGO 136, erythrosin B, nucleotide or nucleotide derivative including AMP, 8 Bus-AMP and 8 Bus-ATP, and analogues thereof.

25. (Currently amended) The method ~~as recited in~~of claim 12 ~~to 23~~, wherein said inhibitor is BGO136 or a BGO136 analogue.

26. (Currently amended) The method ~~as recited in~~of claim 12, wherein said inhibitor is AMP or an AMP analogue.

27. (Currently amended) The method ~~as recited in~~of claim 12, wherein said inhibitor is 8 Bus-AMP.

28. (Currently amended) The method ~~as recited in~~of claim 12, wherein said inhibitor is ATP or an ATP analogue.

29. (Currently amended) The method ~~as recited in~~of claim 12, wherein said inhibitor is 8 Bus-ATP.

30. (Currently amended) The method ~~as recited in~~of claim 12, wherein said inhibitor is erythrosine B or an erythrosin B analogue.

31. (Currently amended) A method to prevent or reduce the risk of rejection of transplanted tissue or organ in a mammal, comprising administering to said animal mammal an effective amount of NTPDase inhibitor, whereby the risk of rejection of transplanted tissue or organ of said mammal is prevented or reduced.

Application No. 11/511,133 – Amendment filed June 11, 2007 in response to Office Action dated January 16, 2007

32. (Currently amended) A ~~The~~ method as ~~recited in~~ claim 31, wherein said NTPDase inhibitor is selected from the group consisting of BGO 136, erythrosin B, nucleotide or nucleotide derivative including AMP, 8 Bus-AMP and 8 Bus-ATP, and analogues thereof.

33. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is BGO136 or a BGO136 analogue.

34. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is AMP or an AMP analogue.

35. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is 8 Bus-AMP.

36. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is (Original) ATP or an ATP analogue.

37. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is 8 Bus-ATP.

38. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is erythrosine B or an erythrosin B analogue.

39. (Currently amended) The method as ~~recited in~~ claim 32, wherein said inhibitor is BGO 136.

40. (Cancelled)

41. (Cancelled)